JVRD Author's Forum Podcast
Welcome to the Journal of Vitreoretinal Diseases (JVRD) Author’s Forum. JVRD is the official scientific peer-reviewed journal of the American Society of Retina Specialists, offering the highest quality and most impactful research and clinical information in the field.
Join JVRD's Editor-in-Chief Dr. Timothy Murray as he discusses cutting-edge developments featured in the journal with authors who share clinical research and explore its significance for advancing patient care.
Audio episodes are available on Amazon Music, Apple Podcasts, Google Podcasts, Spotify and other podcast directories. You can also visit our YouTube channel to watch the dynamic conversations in each episode.
In this episode, Dr. Lejla Vajzovic discusses the impact of e-cigarette use on macular perfusion employing optical coherence tomography angiography (OCTA) in a study of 25 patients. Learn if there are differences in retinal microvasculature measurements in patients using e-cigarettes compared to nonsmoker control groups.
In this episode, Dr. Jennifer Aye discusses a case of recurrent aggressive ciliochoroidal melanoma requiring enucleation after brachytherapy elsewhere for recurrence at the biopsy site. The tumor showed progression from gene expression profiling (GEP) class 1A, PRAME negative to GEP Class 1b.
In this episode, Steven Yeh, MD, University of Nebraska Medical Center, Truhlsen Eye Institute, discusses 3 cases of retinopathy secondary to ritonavir use in the treatment of HIV. The review identified 3 patients with a history of HIV treated with antiretroviral therapy including ritonavir who had been evaluated for bilateral vision loss in both eyes. Explore why ritonavir toxicity should be considered in the differential diagnosis of retinopathy among patients with an exposure history.
On this episode, Dr. Murray welcomes Andre Witkin, MD, Associate Professor, Tufts University School of Medicine, Boston, MA, and chair of the ASRS ReST Committee, to discuss the article, Retinal Vasculitis After Intravitreal Pegcetacoplan: Report From the ASRS Research and Safety in Therapeutics (ReST) Committee.
On February 17, 2023, pegcetacoplan 15mg (Syfovre – Apellis Pharmaceuticals, Waltham MA) was approved by the US Food and Drug Administration (FDA) to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Beginning in April 2023, the American Society of Retina Specialists (ASRS) Research and Safety in Therapeutics (ReST) Committee began receiving reports of intraocular inflammation (IOI) following intravitreal pegcetacoplan administration. In addition to cases of IOI without retinal vascular involvement, several reported cases included retinal vasculitis resulting in occlusive retinal vasculopathy and significant vision loss. The American Society of Retina Specialists (ASRS) Research and Safety in Therapeutics (ReST) Committee, as well as an expert panel, performed a retrospective review of cases of retinal vasculitis reported to the ASRS. Clinical and imaging characteristics were reviewed for evidence of retinal vasculitis and analyzed.
On this episode, Dr. Murray welcomes Colin McCannel, MD, from Stein Eye and Doheny Institutes, University of California, Los Angeles, to discuss a case report on the long-term outcomes of 2 cases of primary autologous stem cell transplantation (ASCT) for the treatment of primary central nervous system lymphoma–ophthalmic variant (PCNSL-O) or primary vitreoretinal lymphoma (PVRL). Learn about the testing methods when there was no systemic or central nervous involvement on the workup, and explore the treatment and management of these patients.
On this episode, Dr. Murray welcomes Aleksandra Rachitskaya, MD, FASRS, Cole Eye Institute, Cleveland Clinic, to explore the effect of syringe type on developing sustained intraocular pressure (IOP) increases. Learn how the type of syringe may or may not affect outcomes.
On this episode, Dr. Murray welcomes Dr. Kuppermann, Gavin Herbert Eye Institute, University of California, Irvine, to explore evidence from other specialties regarding cross-switching between biosimilars, and learn if there are any foreseen patient safety concerns for retina specialists.
On this episode, Dr. Murray welcomes R. Rishi Gupta, MD, FRCSC, FASRS, associate professor at Dalhousie University, Halifax, Nova Scotia, to discuss a case report on how a case of postoperative persistent loculated subretinal fluid (SRF) developed after pars plana vitrectomy (PPV) for vitreomacular traction (VMT) syndrome. Explore the management decisions that were used for this rare complication.
On this episode, Dr. Timothy Murray welcomes Xuejing Chen, MD, assistant professor at Boston University School of Medicine, to discuss a study on how the pandemic affected people from variable demographics. Explore the data and learn if the pandemic affected access to intravitreal injection treatments.
On this episode, Dr. Timothy Murray welcomes Sean D. Adrean, MD, from Retina Consultants of Orange County, to discuss a case of retinopathy secondary to intense coughing and vomiting as symptoms of COVID-19. Learn about the diagnosis and eventual surgical management.
On this episode, Dr. Timothy Murray welcomes Daniel M. Miller, MD, PhD, FASRS, of Cincinnati Eye Institute, to discuss a surgical technique that affects patients with port delivery system implants who experience a conjunctival erosion.
On this episode, Dr. Timothy Murray welcomes Sharon Fekrat, MD, FACS, FASRS, Duke University, to discuss a case involving a 29-year-old, obese, hypertensive man who presented with a 10-day history of progressive vision loss in the left eye with no history of trauma. The visual acuity was 20/25 OD and hand motions OS. Learn the importance of one condition in association with PLR does not exclude the presence of another concurrent etiology.
On this episode, Dr. Timothy Murray welcomes Charles C. Wykoff, MD, PhD, FASRS, Retina Consultants of Texas, to discuss the study on the comparison of rates of endophthalmitis (1) following intravitreal injection of antivascular endothelial growth factor therapies with glass-vial preparation (GVP) vs prefilled syringes (PFS) and (2) before and after masking protocols were implemented. Learn if PFS use affected endophthalmitis cases and whether the use of surgical face masks impacts the rate of endophthalmitis.
On this episode, Dr. Timothy Murray welcomes Dr. Audina Berrocal from Bascom Palmer Eye Institute to discuss a recent JVRD case report from the Sept./Oct. issue on preterm newborns with ROP and vitreous opacification thought to be caused by hyperbilirubinemia. Because of vitreous opacification, these patients could not be properly examined for ROP. Explore how treatment with an intravitreal antivascular endothelial growth factor injection might be considered to delay disease development.
On this episode, Dr. Timothy Murray welcomes Dr. Ella Leung, from Georgia Retina, to discuss Medicare reimbursements for the physician work component of vitreoretinal surgeries as a significant opportunity cost for the physician relative to office-based patient care of equivalent time. Explore how the current analysis compares Medicare physician reimbursements for the most common vitreoretinal surgeries against the potential reimbursements the physician could have generated by managing patients in the office.
On this episode, Dr. Timothy Murray welcomes Dr. Caroline Awh, an ophthalmology resident, to discuss a recent JVRD case report from the Sept./Oct. issue on a rare cause of fungal endophthalmitis. Learn how this case poses significant diagnostic and management challenges.
On this episode, Dr. Timothy Murray welcomes Dr. Paul Hahn of NJ Retina to discuss an article from the May/June issue of JVRD on DME treatments between 2015 and 2020 by US retina specialists. Learn whether practice patterns align with conclusions from major randomized DME clinical trials. Real-world outcomes and clinical trial outcomes will be compared.
On this episode, Dr. Timothy Murray welcomes Dr. Mark Seamone from the University of Alberta to discuss an article from the May/June issue of JVRD on surgery success rates of vitrectomy with a macular-off retinal detachment. Learn whether peeling the ILM is the right approach for patients in certain subsets of retinal detachments. Discover whether ILM peeling of the macula in primary, uncomplicated macula-off RRD has a statistically significant benefit in reducing the risk of recurrent RRD.